Compare Adaptive Biotechnologies Corp (ADPT) vs Coursera Inc (COUR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Coursera Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Coursera Inc trades at $5.87 (market cap $1.66B). The key difference: Adaptive Biotechnologies Corp is far larger — about 2× Coursera Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | COUR | |
|---|---|---|
Market Cap | $3.33B | $1.66B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $12.70 |
52-Week Low | $10.24 | $5.09 |
Enterprise Value | $3.19B | $915.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Coursera (COUR) trades at $5.80, down 1.69% today, with a bullish technical signal from moving averages. Revenue grew to $757.5M in 2025, though net income remains negative at -$51M. The company completed its merger with Udemy in May 2026, aiming for synergies, and announced a $500M share repurchase program. Positive cash flow from operations of $108.7M supports financial stability.
The outlook is mixed: analyst consensus targets $8.00 (37.9% upside), with 53% buy ratings, but persistent losses and competitive pressures pose risks. Earnings misses in recent quarters highlight execution challenges. The stock offers growth potential via market expansion and merger benefits, yet profitability concerns and market volatility require cautious evaluation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
